Bristol-Myers Squibb’s Yervoy (ipilimumab) Awarded Prix Galien USA Discovery of the Decade

On Oct 28, 2016

Princeton-based Bristol-Myers Squibb Company announced that it received the Prix Galien USA Discovery of the Decade biotech award for Yervoy (ipilimumab), the Company’s recombinant, human monoclonal antibody. In honor of the 10th anniversary of the Prix Galien awards and recognizing this decade as one of history’s most productive for research, this special honor distinguishes Bristol-Myers Squibb for its innovative discovery and development of Yervoy, which is now approved in more than 50 countries for treatment of unresectable or metastatic melanoma. The award is also a testament to Bristol-Myers Squibb’s efforts to establish Immuno-Oncology as a transformational approach to treating a wide range of malignancies.

“We are honored to receive this special recognition for Yervoy, an agent that ushered in what can easily be described as a historical time in cancer research,” said Francis Cuss, MB, BChir, FRCP, chief scientific officer and executive vice president, Research & Development, Bristol-Myers Squibb. “We are extremely proud that the highly distinguished selection committee recognized the extraordinary vision of our scientists and the strength of our research and development program, which includes a robust portfolio of early assets both in Immuno-Oncology and in targeted therapies.”

The announcement was made during the tenth annual Prix Galien USA Awards Ceremony held on October 27, 2016 in New York City. The Prix Galien Discovery of the Decade award, which is selected by a preeminent scientific committee that includes several Nobel Laureates, honors outstanding achievements in improving the human condition through the development of innovative therapies. This is the third Prix Galien honor received by Bristol-Myers Squibb, the only company to receive the Prix Galien USA Best Biotechnology Product award for two Immuno-Oncology agents. In 2012, Yervoy (ipilimumab) received the Best Biotechnology Product award, following its initial approval for unresectable or metastatic melanoma. In 2015, Opdivo was named Best Biotechnology Product, following its accelerated approval for unresectable or metastatic melanoma and disease progression following treatment with Yervoy and (if BRAF V600 mutation-positive) a BRAF inhibitor. Building on this pioneering science, the Company continues to research the potential of Immuno-Oncology to extend survival in some of the hardest-to-treat cancers.

 

Related Articles: